



ASX Release

20 December 2018

FIRST US-BASED FERTILITY KEY OPINION LEADER, CCRM, APPOINTED TO UNDERTAKE FELIX ASSESSMENT AHEAD OF COMMERCIALISATION

Highlights

- **Memphasys signs MoU with USA-based fertility specialists, Colorado Center of Reproductive Medicine, CCRM, to take part in *in-vitro* assessments of the Felix device.**
- **The study will be led by Dr Mandy Katz-Jaffe, Scientific and Genetics Director at CCRM which is known for leadership in fertility science.**

Australian-based bio-separations company Memphasys Limited (**ASX: MEM**) (“Memphasys” or “the Company”) is pleased to announce it has signed a Memorandum of Understanding (“MoU”) with CCRM, a leader in fertility science and treatments based in Colorado USA, to take part in *in-vitro* assessments of the Felix device.

Under the MoU, the CCRM team - to be led by Dr Mandy Katz-Jaffe, the Scientific and Genetics Director at CCRM, will participate with world-renowned fertility expert and co-inventor of the Felix technology, Prof John Aitken from the University of Newcastle, and Memphasys in the clinical validation of the Felix device in a clinical setting.

Dr. Katz-Jaffe and her research team will work collaboratively with Prof Aitken to validate the Felix system and confirm its application and efficacy in separating spermatozoa under clinical conditions from a range of clinical samples of human semen.

Recently, the Company signed MoUs with two European centres: Stockholm-based leading male infertility clinic and andrology centre, ANOVA (see ASX announcement dated 22 October 2018) and with UCA/GReD, France (see ASX announcement dated 22 November 2018).

As previously outlined, the KOL clinical assessment studies will assess and confirm Felix’s performance for IVF clinics in preparing sperm from diverse semen types when compared with the current lab-based methods, (“density gradient centrifuge” and “swim up”), which are labour intensive, costly and DNA-damaging.

The outcomes of the Felix clinical assessments will provide further evidence as to the technical capabilities and broaden the clinical benefits of the Felix device, provide significant user examples of its range of use and further refine the commercialisation strategy of the Company.

Alison Coutts, Executive Chairman of Memphasys, stated:

“Dr. Mandy Katz-Jaffe and her team from CCRM are renowned for their excellence in reproductive genetics and for achieving outstanding IVF outcomes. We are very excited the CCRM team has agreed to participate in the clinical assessment of the Felix device.

“The recruitment of leading IVF clinics and andrology reference centres in the United States, Europe, Asia and Australia who have initiated their willingness to take part in the Felix assessment is testament to the interest in the device, and recruitment of other leading centres is proceeding well and will be announced shortly.”

Assessment Protocols

Prof Aitken will develop assessment protocols with each IVF clinic and andrology centre. The Felix assessment program is expected to have two protocols at each site - one general protocol for all IVF clinics and andrology centres, comparing the Felix-selected sperm against the quality of sperm selected by current lab methods (Swim Up/ DGC) with routine clinical semen samples; and a second assessing Felix performance for particular types of male infertility of particular interest to each individual IVF clinic or andrology centre.

About CCRM

CRM is a leader in fertility science, research and advancement, offering access to a national network of award-winning physicians, a full suite of fertility services, innovative technology and cutting-edge labs. It operates 11 fertility centres throughout North America. CCRM specialists invented and optimized numerous techniques that are have now become mainstream, including comprehensive chromosome screening (CCS) and *in vitro* culture of human embryos to the blastocyst stage.

ENDS

For further information please contact:

Alison Coutts
Executive Chairman
Memphasys Limited
+61 2 8415 7300
alison.coutts@memphasys.com
About Memphasys:

David Tasker
Managing Director
Chapter One Advisors
+0433 112 936
dtasker@chapteroneadvisors.com.au

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.